Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers have investigated this with promising results. For the first time, it was possible to identify patient ...
VYNE Therapeutics Inc., a Delaware-based biopharmaceutical company, recently disclosed significant developments in its clinical trials concerning VYN202, a novel BD2-Selective BET Inhibitor. The ...
It exhibits pharmaceutically promising properties, including protease resistance, negligible immunogenicity, and a potent inhibitory effect on cell migration. Genetic code expansion and ...
This important study leverages the power of Drosophila genetics and sparsely-labeled neurons to propose a new model for neuronal injury signaling. The authors present convincing evidence to support ...
CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the submission of ...